> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Prestige Consumer Healthcare's Tax Rate Hits 46.7% As Acquisition Debt Triples Interest Costs
- URL: https://www.bullished.co/prestige-consumer-healthcares-tax-rate-hits-46-7-as-acquisition-debt-triples-interest-4c18ae13/
- Published: 2026-11-05T11:36:47.000Z
- Updated: 2026-11-05T11:36:47.000Z
- Description: A valuation allowance and $2.1 billion of debt cut reported earnings to $0.53 a share, while the adjusted figure rose to $1.13.
- Author: Matteo Parrino
- Tags: Deals, PBH, Industry: Healthcare

[Prestige Consumer Healthcare](https://www.bullished.co/tag/pbh/), which sells brands such as Clear Eyes and Breathe Right, saw its [effective tax rate reach 46.7%](https://www.sec.gov/Archives/edgar/data/0001295947/000129594726000057/pbh-20260930.htm?ref=bullished.co) in the September quarter, up from 38.9% a year earlier, after it set up a valuation allowance against deferred tax assets, its 10-Q filed Thursday shows. Quarterly interest expense meanwhile reached $30.0 million, three times the year-earlier level, as borrowing for acquisitions swelled the debt load.

## Tax rate and interest squeeze profit

A valuation allowance is an accounting reserve against tax assets the company may not be able to use. The 10-Q says it was the main reason the rate rose, both for the quarter and for the six months, when the rate was 36.7% versus 31.5%. The prior quarter's [10-Q](https://www.sec.gov/Archives/edgar/data/0001295947/000129594726000042/pbh-20260630.htm?ref=bullished.co) had put the rate at 24.3% and cited other drivers.

Pretax income fell to $47.5 million from $69.1 million. [Net income was $25.3 million](https://www.globenewswire.com/news-release/2026/11/05/3396163/0/en/prestige-consumer-healthcare-inc-reports-fiscal-2027-second-quarter-results.html?ref=bullished.co), or $0.53 a share, against $42.2 million, or $0.86, a year earlier.

Interest expense was $30.0 million versus $10.0 million. Average debt reached $2.1 billion from $1.0 billion, and the average borrowing cost rose to 5.6% from 4.5%. The company also booked a $1.4 million loss on retiring its 2019 notes, replaced by $400.0 million of 6.250% notes due 2034.

## Adjusted EPS tells a different story

The company's [earnings release](https://www.sec.gov/Archives/edgar/data/0001295947/000129594726000055/exhibit991fy27-q2earningsr.htm?ref=bullished.co) put adjusted diluted EPS at $1.13, versus $1.07 a year ago. That adjusted figure adds back a $10.6 million normalized tax adjustment tied to the allowance, worth $0.22 a share, along with acquisition and Pillar5 facility costs.

[Revenue rose 22.7%](https://www.globenewswire.com/news-release/2026/11/05/3396163/0/en/prestige-consumer-healthcare-inc-reports-fiscal-2027-second-quarter-results.html?ref=bullished.co) to $336.3 million. Excluding currency and a $65.1 million contribution from the Breathe Right and LaCorium acquisitions, it fell 1.6%, which the company tied to order timing and a decline in Clear Eyes. The 10-Q says shortages, especially of sterile eye care products, have hurt results.

## Debt-funded buying spree

Prestige, which sells branded over-the-counter health products through retailers and e-commerce, has grown largely by acquisition. It bought Pillar5, a sterile eye-drop maker, in December 2025 for $109.9 million. It bought Breathe Right and other brands on June 12 for $1,044.9 million in cash, funded with a term loan. It bought Australia's LaCorium Health on July 1 for $152.1 million, borrowing another $95.0 million.

Total debt stood at $2.1 billion at September 30, and cash was $46.5 million. The company cut its fiscal 2027 outlook to $1,280 million to $1,290 million in revenue and $4.48 to $4.55 in adjusted EPS, citing variable Clear Eyes production at Pillar5.

Net receivables grew to $244.1 million from $191.9 million, while the credit-loss allowance against them increased to $24.1 million from $18.2 million.

### Sources

- [10-Q Filing — Prestige Consumer Healthcare (PBH)](https://www.sec.gov/Archives/edgar/data/0001295947/000129594726000057/pbh-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Prestige Consumer Healthcare (PBH), Q1 FY2027 filed 2026-08-06 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001295947/000129594726000042/pbh-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, exhibit991fy27-q2earningsr.htm) — Prestige Consumer Healthcare, filed 2026-11-05](https://www.sec.gov/Archives/edgar/data/0001295947/000129594726000055/exhibit991fy27-q2earningsr.htm?ref=bullished.co) — SEC EDGAR
- [Prestige Consumer Healthcare: Fiscal Q2 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/prestige-consumer-healthcare-fiscal-q2-earnings-snapshot/616-97982add-3306-4774-999b-a2b1636918b5?ref=bullished.co) — Associated Press
- [biote Corp. (BTMD) Tops Q3 Earnings Estimates](https://finance.yahoo.com/healthcare/articles/biote-corp-btmd-tops-q3-215004895.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Prestige Consumer Healthcare Inc. Reports Fiscal 2027](https://www.globenewswire.com/news-release/2026/11/05/3396163/0/en/prestige-consumer-healthcare-inc-reports-fiscal-2027-second-quarter-results.html?ref=bullished.co) — globenewswire.com

### More on Prestige Consumer Healthcare

- [Prestige Consumer Healthcare Cuts Revenue Outlook To $1,280 Million-$1,290 Million As Clear Eyes Supply Stays Tight](https://www.bullished.co/prestige-consumer-healthcare-cuts-revenue-outlook-to-1-280-million-1-290-million-as-clear-52816b09/)

[All Prestige Consumer Healthcare (PBH) coverage →](https://www.bullished.co/tag/pbh/)